Understanding Endotoxin Levels in Biologics: Regulatory Trends and the Role of Reference Drugs

As biologic formats and formulations grow more complex, so do the challenges of endotoxin testing and control. Clinical-grade reference drugs, derived from licensed biologics, provide valuable context for understanding endotoxin limits and ensuring patient-safety. Let’s take a closer look at how these reference drugs enable comparison of accepted endotoxin levels across biologic formulations, routes of administration, dosage regimens, and therapeutic indications. 

Why is endotoxin control critical to biologic purity? 

Biologic products are produced using living expression systems, which inherently introduce a range of intrinsic and extrinsic impurities. Among these, bacterial endotoxins pose one of the most significant safety risks. Endotoxin contamination can originate from non-sterile raw materials, excipients, process water, buffers, or solvents. It can also arise endogenously in gram-negative bacterial expression systems such as Escherichia coli, where cell wall lysis during fermentation or purification can release large quantities of endotoxins into the product stream. 

Endotoxins are mainly amphiphilic lipopolysaccharides (LPS) found in the outer membrane of gram-negative bacteria. They are pyrogens and can activate TLR response, leading to inflammation, fever, and sometimes shock and organ failure. Since endotoxins are heat-stable and resistant to standard sterilization, their control requires robust preventive strategies and continuous monitoring. Meticulous downstream purification and stringent endotoxin testing is implemented at critical points in the manufacturing process. From a Quality by Design (QbD) manufacturing standpoint, it is preferable to develop processes that proactively prevent endotoxin contamination rather than depending on downstream removal steps. Additionally, it is important to tailor endotoxin testing strategies to the particular biologic product and process being developed. 

In this context, clinical-grade reference drugs, which are derived from the licensed biologics that are used by patients, serve as ideal comparators for evaluating endotoxin levels considered safe by regulatory agencies for specific formulations and dosing regimens. These reference drugs represent real-world, regulatory-approved formulations with established pyrogenic safety profiles. By providing clinically validated endotoxin baselines, they enable biologic developers to set risk-appropriate thresholds, validate analytical methods, and design in-vivo experiments with greater reliability. 

Detecting endotoxins: From conventional methods to modern harmonization 

When an investigational new drug (IND) or biologics license application (BLA) is submitted, it is important to include controls on pyrogens – including endotoxins - as a part of the chemistry, manufacturing, and control information. Now that biologic therapies are evolving beyond monoclonal antibodies to antibody–drug conjugates, bispecifics, and fragments, regulatory authorities are currently aligning on harmonized testing methods. At the same time, acceptance criteria are shifting toward a patient-centric approach. 

There are two main methods which have been widely used to detect endotoxin levels during biologic drug development.   These include: 

1. Rabbit pyrogen test (RPT): RPT is used for qualitative in-vivo detection of pyrogens, as rabbits have similar pyrogen tolerance to humans. This test identifies pyrogens by monitoring rabbit body temperature changes and can detect non-bacterial endotoxins. There are some drawbacks, however. The test is time-consuming, requires many rabbits, cannot quantify endotoxins, and may yield false positives or negatives due to other pyrogens or inactive endotoxins.   
2. Bacterial Endotoxins Test (BET): Also known as the Limulus Amebocyte Lysate (LAL) test, this in-vitro assay detects endotoxins from Gram-negative bacteria by using horseshoe crab amoebocyte lysate, which triggers Factor C-mediated clotting. LAL was approved by the US FDA in 1983 and includes three methods: (a) gel-clot, based on gel formation; (b) turbidimetric, which measures turbidity; and (c) chromogenic, which assesses color development after substrate cleavage. Both gel-clot and chromogenic methods are suitable for all stages of therapeutic product development, including biologics like monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapies.  

BET is harmonized across major pharmacopoeias, including the United States Pharmacopeia (USP <85>), the European Pharmacopoeia (Ph. Eur. 2.6.14), and the Japanese Pharmacopoeia (JP 4.01). This makes these standards interchangeable within ICH regions when applied under the prescribed conditions. 

However, the regulatory authorities are encouraging non-animal derived reagent approaches. The new tests in this approach include: 

1. Monocyte Activation Test (MAT): It is an in-vitro alternative to RPT and can detect both endotoxin and non-endotoxin pyrogens by measuring the release of cytokines (such as IL-6, IL-1β, and TNF-α) from human monocytes or whole blood upon exposure to a test sample.  
2. Recombinant Factor C (rFC) Assay: It is an in-vitro alternative to LAL using the recombinant enzyme for endotoxin-sensitive coagulation cascade, producing a quantifiable fluorescent or chromogenic signal proportional to endotoxin concentration. 

The European Pharmacopoeia has taken significant steps to reduce animal testing, introducing the MAT < Chapter 5.1.13> as an alternative to the RPT in 2009. Effective from July 1, 2025, RPT will be fully phased out and removed from the pharmacopoeia by January 2026. Similarly, effective May 2025, USP <Chapter 86> adopts rFC as an alternative to LAL test.  

The low endotoxin recovery (LER) phenomenon has also been described for LAL tests. LER is the inability to recover known amounts of purified endotoxin from biological formulations and can be caused by the presence of chelating agents and surfactants (e.g., polysorbate and citrate) in biological formulations. The LER phenomenon can be evaluated using specific study designs or analytical approaches using suitable reference standard endotoxin, control standard endotoxin, and naturally occurring endotoxin.  

Endotoxin acceptance criteria: A shift towards a patient–centric framework  

Generally speaking, endotoxin acceptance criteria are set such that the endotoxin administration level does not exceed the pyrogenic threshold. Endotoxin limit (EL) is calculated by K/M, where K = Threshold Pyrogenic Dose, and M = Dose of the drug in units/kg/hr. 

As listed in as listed in USP <85>, for intravenous and subcutaneous administration, the upper limit is set at 5 EU (endotoxin units)/kg body weight/hour or 100 EU/m2 body surface/hour. For intrathecal, the threshold is set at 0.2 EU/kg body weight/hour. These values denote the maximum combined endotoxin exposure level from all agents, provided there is no clinically significant increase in body temperature at these exposures.  

When determining acceptance criteria for endotoxins during development, important factors such as the intended dose and route of administration should be considered. 

• For lyophilized drugs and diluted products: It is necessary to account for the endotoxin contribution from the diluent or reconstitution fluid when setting the acceptance threshold.  

• For combination therapies: When two or more biologics are given together to achieve a synergistic clinical effect, particularly in oncology, the total endotoxin levels from all drugs need to be evaluated. If the EU exceeds recommended limits, reducing dosages or administering drugs in phases may be alternative treatment strategies. 

Balancing patient safety and practicality  

Some regulatory authorities recommend using the lowest patient body weight and tightening endotoxin limits to address concerns such as LER. However, imposing overly stringent limits may result in unnecessary out-of-specification findings and disrupt product availability, ultimately impacting patient access to essential therapies. 

A more balanced, patient-centric strategy involves calculating endotoxin limits according to pharmacopeial guidelines, while comprehensively considering all potential sources of endotoxins, including packaging, devices, and diluents, to ensure safety without excessive restriction. Additionally, regional or population-specific considerations are viable; for instance, the United States Pharmacopeia allows the use of average body weight for relevant populations (e.g., 70 kg in the U.S., 60 kg in Japan), aligning with international regulatory practices. 

According to a recent publication in BioProcess International by Bindra et al., 2025, the standard threshold pyrogenic dose of 5 EU/kg/h, historically established from studies involving purified E. coli endotoxin, incorporates a substantial inherent safety margin. Environmental endotoxins present in pharmaceutical products are generally significantly less potent, resulting in at least an eight-fold safety buffer. Furthermore, adverse events attributable to endotoxins are extremely rare, supporting the appropriateness of using average patient body weight for calculation.

Using clinical-grade reference drugs to evaluate accepted endotoxin levels 

Clinical-grade reference drugs, sourced from approved biologics with established safety profiles, serve as valuable benchmarks for assessing acceptable endotoxin levels across different formulations, routes of administration, dosages, and therapeutic uses. 

Using these reference materials as comparators enables developers to translate analytical endotoxin data (EU/mL) into clinically meaningful risk assessments, aligning the product’s intended formulation, dose, and route with human-tolerated safety thresholds. Additionally, they are low-toxicity, GMP-produced, and pyrogen-tested, making them well suited for in-vivo preclinical studies, including pharmacokinetic, pharmacodynamic, and toxicity evaluations, by minimizing interference and improving physiological relevance.  

Clinical-grade reference drugs from qualified suppliers, like Evidentic, are available in multiple batches and formulations (liquid and lyophilized), enabling developers to assess batch-to-batch consistency and formulation-dependent variability. This offers a practical framework for understanding clinically relevant variation across comparable biologic products and therapeutic indications.  

As biopharmaceuticals continue to diversify, reference materials derived from approved drugs support a more informed approach to defining endotoxin limits during formulation and product development. Aligning new or related candidates with clinically validated standards enhances quality assurance and reinforces patient safety across established and emerging therapeutic areas. 

References: 

1. Limpikirati PK, Mongkoltipparat S, Denchaipradit T, et al. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics. J Pharm Anal. 2024;14(6):100916. doi:10.1016/j.jpha.2023.12.006 
2. Bindra D, Blumel M, Kearns K, van Montfort B, Newman A, Yang H. Establishing Patient-Centric Endotoxin Acceptance Criteria: An Industry Opinion. BioProcess International. Published September 2, 2025. Accessed October 30, 2025. https://www.bioprocessintl.com/bioanalytical-methods/establishing-patient-centric-endotoxin-acceptance-criteria-an-industry-opinion 
3. US FDA. Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry. JULY 2020.   
4. US FDA. Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers. June 2012.  
5. Williams KL. The Biologics Revolution and Endotoxin Test Concerns. Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems. 2019;331-402. Published 2019 Mar 18. doi:10.1007/978-3-030-17148-3_8  
6. Suvarna K. Endotoxin Detection Methods – Where are we now? American Pharmaceutical Review. August 25, 2015.  
7. Setting Endotoxin Acceptance Criteria for Biologics Intravenous (IV) and Subcutaneous (SC) Mono- and Combination Therapies. American Pharmaceutical Review. September 17, 2018. 
8. Solati S, Zhang T, Timman S. The monocyte activation test detects potentiated cytokine release resulting from the synergistic effect of endotoxin and non-endotoxin pyrogens. Innate Immun. 2022;28(3-4):130-137. doi:10.1177/17534259221097948 
9. Kang DH, Yun SY, Eum S, et al. A Study on the Application of Recombinant Factor C (rFC) Assay Using Biopharmaceuticals. Microorganisms. 2024;12(3):516. Published 2024 Mar 4. doi:10.3390/microorganisms12030516 
10. Bolden J, Knight M, Montz J, One J, Stockman S, Jones SP. It is time to reconsider the use of naturally-occurring endotoxins in endotoxin recovery studies: Part 2 of a BioPhorum harmonized endotoxin recovery study. Biologicals. 2024;87:101779. doi:10.1016/j.biologicals.2024.101779